| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | VSIG1 |
| Uniprot No | Q86XK7 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 22-232aa |
| 氨基酸序列 | VQVTIPDGFVNVTVGSNVTLICIYTTTVASREQLSIQWSFFHKKEMEPISIYFSQGGQAVAIGQFKDRITGSNDPGNASITISHMQPADSGIYICDVNNPPDFLGQNQGILNVSVLVKPSKPLCSVQGRPETGHTISLSCLSALGTPSPVYYWHKLEGRDIVPVKENFNPTTGILVIGNLTNFEQGYYQCTAINRLGNSSCEIDLTSSHPE |
| 预测分子量 | 26.4 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于VSIG1重组蛋白的模拟参考文献示例(实际文献可能需要通过学术数据库检索确认)：
1. **文献名称**：*VSIG1 functions as a tumor suppressor in gastric cancer by regulating cell adhesion and polarity*
**作者**：Zhang Y, et al.
**摘要**：本研究通过重组VSIG1蛋白体外实验，证明其通过结合Claudin-7维持上皮细胞极性，抑制胃癌细胞迁移和侵袭。实验表明VSIG1缺失导致细胞间连接破坏，促进肿瘤进展。
2. **文献名称**：*Recombinant VSIG1 protein inhibits T-cell activation via modulating immune checkpoint pathways*
**作者**：Li H, et al.
**摘要**：首次成功表达并纯化功能性VSIG1重组蛋白，发现其通过与T细胞表面受体相互作用抑制T细胞增殖及炎性因子分泌，提示VSIG1可能作为新型免疫检查点调控分子。
3. **文献名称**：*Structural and functional characterization of the VSIG1 extracellular domain*
**作者**：Wang X, et al.
**摘要**：通过重组表达VSIG1胞外域蛋白，解析其晶体结构，揭示其免疫球蛋白样结构域的关键功能位点，并验证其在细胞粘附和凋亡信号传导中的作用。
4. **文献名称**：*VSIG1 recombinant protein attenuates colitis in murine models by regulating intestinal barrier integrity*
**作者**：Chen L, et al.
**摘要**：利用重组VSIG1蛋白治疗实验性结肠炎小鼠，发现其通过增强肠道上皮紧密连接蛋白表达，减少炎症因子浸润，改善肠屏障功能。
---
**注意**：以上文献为示例性内容，实际研究可能存在差异。建议通过PubMed、Web of Science等平台，以“VSIG1 recombinant protein”或“VSIG1 function”为关键词检索最新文献。
VSIG1 (V-set and immunoglobulin domain-containing protein 1) is a transmembrane protein belonging to the immunoglobulin superfamily (IgSF), characterized by its extracellular V-set and Ig-like domains. It is predominantly expressed in epithelial tissues, particularly in the gastrointestinal tract, and plays critical roles in maintaining cell-cell adhesion, tissue polarity, and barrier integrity. Structurally, VSIG1 interacts with components of tight junctions and adherens junctions, suggesting its involvement in regulating epithelial architecture and permeability. Emerging studies highlight its function as a potential tumor suppressor, with downregulation observed in multiple cancers, including gastric, colorectal, and hepatocellular carcinomas. Its loss is associated with enhanced epithelial-mesenchymal transition (EMT), metastasis, and poor prognosis.
Recombinant VSIG1 protein, typically produced via mammalian expression systems (e.g., HEK293 or CHO cells) to ensure proper post-translational modifications, retains functional domains for biochemical and cellular studies. Researchers utilize it to investigate VSIG1’s role in cell adhesion signaling, its interaction partners (e.g., claudins, occludin), and its regulatory effects on Wnt/β-catenin and TGF-β pathways. Additionally, recombinant VSIG1 serves as an antigen for antibody development, aiding diagnostic assays and therapeutic exploration. Recent interest focuses on its potential as an immune checkpoint molecule, given IgSF proteins’ roles in immune modulation. Despite progress, VSIG1’s precise mechanisms in tissue homeostasis and disease remain incompletely understood, necessitating further research to unlock its translational potential in cancer therapy and regenerative medicine.
×
